Genetic variants in cytosolic 5́-nucleotidase II are associated with its expression and cytarabine sensitivity in HapMap cell lines and in patients with acute myeloid leukemia

Journal of Pharmacology and Experimental Therapeutics

Volumn 339, Issue 1, 2011, Pages 9-23

  Mitra, Amit K ^a   Crews, Kristine R ^b   Pounds, Stanley ^b   Cao, Xueyuan ^b   Feldberg, Tanya ^a   Ghodke, Yogita ^a   Gandhi, Varsha ^c   Plunkett, William ^c   Dolan, M Eileen ^d   Hartford, Christine ^b   Raimondi, Susana ^b   Campana, Dario ^b   Downing, James ^b   Rubnitz, Jeffrey E ^b   Ribeiro, Raul C ^b   Lamba, Jatinder K ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

^b ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5' NUCLEOTIDASE; CYTARABINE; CYTOSOLIC 5' NUCLEOTIDASE II; DAUNORUBICIN; ETOPOSIDE; GENOMIC DNA; MESSENGER RNA; UNCLASSIFIED DRUG;

5' UNTRANSLATED REGION; ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; BLAST CELL; CAUCASIAN; CHILD; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG MEGADOSE; DRUG RESPONSE; DRUG SENSITIVITY; FUNCTIONAL GENOMICS; GENE DELETION; GENE EXPRESSION; GENE INSERTION; GENE LINKAGE DISEQUILIBRIUM; GENE SEQUENCE; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE MAP; HUMAN; HUMAN CELL; LOW DRUG DOSE; NEGRO; PRIORITY JOURNAL; PROTEIN DNA BINDING; RACE DIFFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM;

5'-NUCLEOTIDASE; ANTIMETABOLITES, ANTINEOPLASTIC; BASE SEQUENCE; BLOTTING, WESTERN; CELL LINE; CELL LINE, TUMOR; CHILD; CYTARABINE; CYTOSOL; DNA; ELECTROPHORETIC MOBILITY SHIFT ASSAY; EXONS; GENETIC VARIATION; HUMANS; LEUKEMIA, MYELOID, ACUTE; LUCIFERASES; METHYLATION; MOLECULAR SEQUENCE DATA; POLYMORPHISM, SINGLE NUCLEOTIDE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TRANSCRIPTION FACTORS;

EID: 80053148504     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.111.182873     Document Type: Article

References (37)

1. Amici A, Emanuelli M, Magni G, Raffaelli N, and Ruggieri S (1997) Pyrimidine nucleotidases from human erythrocyte possess phosphotransferase activities specific for pyrimidine nucleotides. FEBS Lett 419:263-267. (Pubitemid 28010823)
2. Amici A and Magni G (2002) Human erythrocyte pyrimidine 5′-nucleotidase, PN-I. Arch Biochem Biophys 397:184-190. (Pubitemid 34852279)
3. Children's Oncology Group, Aplenc R, Alonzo TA, Gerbing RB, Smith FO, Meshinchi S, Ross JA, Perentesis J, Woods WG, Lange BJ, et al. (2006) Ethnicity and survival in childhood acute myeloid leukemia: a report from the Children's Oncology Group. Blood 108:74-80.
4. Beesley AH, Palmer ML, Ford J, Weller RE, Cummings AJ, Freitas JR, Firth MJ, Perera KU, De Klerk NH, and Kees UR (2006) Authenticity and drug resistance in a panel of acute lymphoblastic leukaemia cell lines. Br J Cancer 95:1537-1544. (Pubitemid 44863357)
5. Bianchi V, Pontis E, and Reichard P (1986) Interrelations between substrate cycles and de novo synthesis of pyrimidine deoxyribonucleoside triphosphates in 3T6 cells. Proc Natl Acad Sci USA 83:986-990. (Pubitemid 16086398)
6. Crews KR, Gandhi V, Srivastava DK, Razzouk BI, Tong X, Behm FG, Plunkett W, Raimondi SC, Pui CH, Rubnitz JE, et al. (2002) Interim comparison of a continuous infusion versus a short daily infusion of cytarabine given in combination with cladribine for pediatric acute myeloid leukemia. J Clin Oncol 20:4217-4224. (Pubitemid 35191024)
7. Dumontet C, Fabianowska-Majewska K, Mantincic D, Callet Bauchu E, Tigaud I, Gandhi V, Lepoivre M, Peters GJ, Rolland MO, Wyczechowska D, et al. (1999) Common resistance mechanisms to deoxynucleoside analogues in variants of the human erythroleukaemic line K562. Br J Haematol 106:78-85.
8. Galmarini CM (2007) What does over-expression of cN-II enzyme signify in haematological malignancies? Leuk Res 31:1325-1326.
9. Galmarini CM, Cros E, Thomas X, Jordheim L, and Dumontet C (2005) The prognostic value of cN-II and cN-III enzymes in adult acute myeloid leukemia. Haematologica 90:1699-1701. (Pubitemid 41814998)
10. m 5′-nucleotidase in leukemic blasts is an independent prognostic factor in adults with acute myeloid leukemia. Blood 98:1922-1926.
11. Galmarini CM, Mackey JR, and Dumontet C (2001b) Nucleoside analogues: mechanisms of drug resistance and reversal strategies. Leukemia 15:875-890. (Pubitemid 32529886)
12. Galmarini CM, Thomas X, Graham K, El Jafaari A, Cros E, Jordheim L, Mackey JR, and Dumontet C (2003) Deoxycytidine kinase and cN-II nucleotidase expression in blast cells predict survival in acute myeloid leukaemia patients treated with cytarabine. Br J Haematol 122:53-60. (Pubitemid 36819338)
13. Hartford CM, Duan S, Delaney SM, Mi S, Kistner EO, Lamba JK, Huang RS, and Dolan ME (2009) Population-specific genetic variants important in susceptibility to cytarabine arabinoside cytotoxicity. Blood 113:2145-2153.
14. Holleman A, Cheok MH, Den Boer ML, Yang W, Veerman AJ, Kazemier KM, Pei D, Cheng C, Pui CH, Relling MV, et al. (2004) Gene-expression patterns in drugresistant acute lymphoblastic leukemia cells and response to treatment. N Engl J Med 351:533-542.
15. Jung SH, Owzar K, and George SL (2005) A multiple testing procedure to associate gene expression levels with survival. Stat Med 24:3077-3088. (Pubitemid 41489422)
16. Kufe DW, Major PP, Egan EM, and Beardsley GP (1980) Correlation of cytotoxicity with incorporation of ara-C into DNA. J Biol Chem 255:8997-9000. (Pubitemid 11202866)
17. Lamba JK, Crews K, Pounds S, Schuetz EG, Gresham J, Gandhi V, Plunkett W, Rubnitz J, and Ribeiro R (2007) Pharmacogenetics of deoxycytidine kinase: identification and characterization of novel genetic variants. J Pharmacol Exp Ther 323:935-945. (Pubitemid 350146062)
18. Lamba JK, Crews KR, Pounds SB, Cao X, Gandhi V, Plunkett W, Razzouk BI, Lamba V, Baker SD, Raimondi SC, et al. (2011) Identification of predictive markers of cytarabine response in AML by integrative analysis of gene-expression profiles with multiple phenotypes. Pharmacogenomics 12:327-339.
19. Li L, Fridley BL, Kalari K, Jenkins G, Batzler A, Weinshilboum RM, and Wang L (2009) Gemcitabine and arabinosylcytosin pharmacogenomics: genome-wide association and drug response biomarkers. PLoS One 4:e7765.
20. Major PP, Egan EM, Beardsley GP, Minden MD, and Kufe DW (1981) Lethality of human myeloblasts correlates with the incorporation of arabinofuranosylcytosine into DNA. Proc Natl Acad Sci USA 78:3235-3239. (Pubitemid 11032022)
21. Mazzon C, Rampazzo C, Scaini MC, Gallinaro L, Karlsson A, Meier C, Balzarini J, Reichard P, and Bianchi V (2003) Cytosolic and mitochondrial deoxyribonucleotidases: activity with substrate analogs, inhibitors and implications for therapy. Biochem Pharmacol 66:471-479. (Pubitemid 36937032)
22. Ng PC and Henikoff S (2001) Predicting deleterious amino acid substitutions. Genome Res 11:863-874. (Pubitemid 32447869)
23. Ng PC and Henikoff S (2003) SIFT: Predicting amino acid changes that affect protein function. Nucleic Acids Res 31:3812-3814. (Pubitemid 37442253)
24. Nickerson DA, Tobe VO, and Taylor SL (1997) PolyPhred: automating the detection and genotyping of single nucleotide substitutions using fluorescence-based resequencing. Nucleic Acids Res 25:2745-2751. (Pubitemid 27299787)
25. Pesi R, Turriani M, Allegrini S, Scolozzi C, Camici M, Ipata PL, and Tozzi MG (1994) The bifunctional cytosolic 5′-nucleotidase: regulation of the phosphotransferase and nucleotidase activities. Arch Biochem Biophys 312:75-80.
26. Pounds S, Cao X, Cheng C, Yang JJ, Campana D, Pui CH, Evans WE, and Relling MV (2011) Integrated analysis of pharmacologic, clinical and SNP microarray data using Projection Onto the Most Interesting Statistical Evidence with Adaptive Permutation Testing. Int J Data Min Bioinform 5:143-157.
27. Pounds S, Cheng C, Cao X, Crews KR, Plunkett W, Gandhi V, Rubnitz J, Ribeiro RC, Downing JR, and Lamba J (2009) PROMISE: a tool to identify genomic features with a specific biologically interesting pattern of associations with multiple endpoint variables. Bioinformatics 25:2013-2019.
28. Ramensky V, Bork P, and Sunyaev S (2002) Human non-synonymous SNPs: server and survey. Nucleic Acids Res 30:3894-3900. (Pubitemid 35012462)
29. Raza A, Gezer S, Anderson J, Lykins J, Bennett J, Browman G, Goldberg J, Larson R, Vogler R, and Preisler HD (1992) Relationship of [3H]Ara-C incorporation and response to therapy with high-dose Ara-C in AML patients: a Leukemia Intergroup study. Exp Hematol 20:1194-1200.
30. Rubnitz JE, Crews KR, Pounds S, Yang S, Campana D, Gandhi VV, Raimondi SC, Downing JR, Razzouk BI, Pui CH, et al. (2009) Combination of cladribine and cytarabine is effective for childhood acute myeloid leukemia: results of the St Jude AML97 trial. Leukemia 23:1410-1416.
31. Rubnitz JE, Inaba H, Dahl G, Ribeiro RC, Bowman WP, Taub J, Pounds S, Razzouk BI, Lacayo NJ, Cao X, et al. (2010) Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial. Lancet Oncol 11:543-552.
32. Schirmer M, Stegmann AP, Geisen F, and Konwalinka G (1998) Lack of crossresistance with gemcitabine and cytarabine in cladribine-resistant HL60 cells with elevated 5′-nucleotidase activity. Exp Hematol 26:1223-1228. (Pubitemid 28541765)
33. Sunyaev S, Ramensky V, and Bork P (2000) Towards a structural basis of human non-synonymous single nucleotide polymorphisms. Trends Genet 16:198-200. (Pubitemid 30216541)
34. Sunyaev S, Ramensky V, Koch I, Lathe W 3rd, Kondrashov AS, and Bork P (2001) Prediction of deleterious human alleles. Hum Mol Genet 10:591-597. (Pubitemid 32229363)
35. Suzuki K, Sugawara T, Oyake T, Uchiyama T, Aoki Y, Tsukushi Y, Onodera S, Ito S, Murai K, and Ishida Y (2007) Clinical significance of high-Km 5′-nucleotidase (cN-II) mRNA expression in high-risk myelodysplastic syndrome. Leuk Res 31: 1343-1349. (Pubitemid 47212425)
36. Wang JJ, Selawry OS, Vietti TJ, and Bodey GP Sr (1970) Prolonged infusion of arabinosyl cytosine in childhood leukemia. Cancer 25:1-6.
37. Wolfinger RD (1996) Heterogeneous variance-covariance structures for repeated measures. J Agric Biol-Environ Sci 1:205-230.